Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Dipeptidyl-Peptidase IV Inhibitors"" wg kryterium: Temat


Tytuł :
Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease.
Autorzy :
Farag SS; From the Indiana University School of Medicine (S.S.F., M.A.Z., J.E.S., R.A., M.J.R., H.E.B., S.Z.), Indiana University Health (S.S.F., M.A.Z., J.E.S., T.C.T., R.A., M.J.R.), and Indiana University Simon Comprehensive Cancer Center (S.S.F., A.J.B., H.E.B.) - all in Indianapolis.
Abu Zaid M; From the Indiana University School of Medicine (S.S.F., M.A.Z., J.E.S., R.A., M.J.R., H.E.B., S.Z.), Indiana University Health (S.S.F., M.A.Z., J.E.S., T.C.T., R.A., M.J.R.), and Indiana University Simon Comprehensive Cancer Center (S.S.F., A.J.B., H.E.B.) - all in Indianapolis.
Schwartz JE; From the Indiana University School of Medicine (S.S.F., M.A.Z., J.E.S., R.A., M.J.R., H.E.B., S.Z.), Indiana University Health (S.S.F., M.A.Z., J.E.S., T.C.T., R.A., M.J.R.), and Indiana University Simon Comprehensive Cancer Center (S.S.F., A.J.B., H.E.B.) - all in Indianapolis.
Thakrar TC; From the Indiana University School of Medicine (S.S.F., M.A.Z., J.E.S., R.A., M.J.R., H.E.B., S.Z.), Indiana University Health (S.S.F., M.A.Z., J.E.S., T.C.T., R.A., M.J.R.), and Indiana University Simon Comprehensive Cancer Center (S.S.F., A.J.B., H.E.B.) - all in Indianapolis.
Blakley AJ; From the Indiana University School of Medicine (S.S.F., M.A.Z., J.E.S., R.A., M.J.R., H.E.B., S.Z.), Indiana University Health (S.S.F., M.A.Z., J.E.S., T.C.T., R.A., M.J.R.), and Indiana University Simon Comprehensive Cancer Center (S.S.F., A.J.B., H.E.B.) - all in Indianapolis.
Abonour R; From the Indiana University School of Medicine (S.S.F., M.A.Z., J.E.S., R.A., M.J.R., H.E.B., S.Z.), Indiana University Health (S.S.F., M.A.Z., J.E.S., T.C.T., R.A., M.J.R.), and Indiana University Simon Comprehensive Cancer Center (S.S.F., A.J.B., H.E.B.) - all in Indianapolis.
Robertson MJ; From the Indiana University School of Medicine (S.S.F., M.A.Z., J.E.S., R.A., M.J.R., H.E.B., S.Z.), Indiana University Health (S.S.F., M.A.Z., J.E.S., T.C.T., R.A., M.J.R.), and Indiana University Simon Comprehensive Cancer Center (S.S.F., A.J.B., H.E.B.) - all in Indianapolis.
Broxmeyer HE; From the Indiana University School of Medicine (S.S.F., M.A.Z., J.E.S., R.A., M.J.R., H.E.B., S.Z.), Indiana University Health (S.S.F., M.A.Z., J.E.S., T.C.T., R.A., M.J.R.), and Indiana University Simon Comprehensive Cancer Center (S.S.F., A.J.B., H.E.B.) - all in Indianapolis.
Zhang S; From the Indiana University School of Medicine (S.S.F., M.A.Z., J.E.S., R.A., M.J.R., H.E.B., S.Z.), Indiana University Health (S.S.F., M.A.Z., J.E.S., T.C.T., R.A., M.J.R.), and Indiana University Simon Comprehensive Cancer Center (S.S.F., A.J.B., H.E.B.) - all in Indianapolis.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Jan 07; Vol. 384 (1), pp. 11-19.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
Graft vs Host Disease/*prevention & control
Hematopoietic Stem Cell Transplantation/*adverse effects
Sitagliptin Phosphate/*therapeutic use
Adult ; Dipeptidyl-Peptidase IV Inhibitors/administration & dosage ; Dipeptidyl-Peptidase IV Inhibitors/adverse effects ; Drug Therapy, Combination ; Female ; Humans ; Immunosuppressive Agents/therapeutic use ; Leukemia, Myeloid/therapy ; Male ; Middle Aged ; Myelodysplastic Syndromes/therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Recurrence ; Sirolimus/therapeutic use ; Sitagliptin Phosphate/administration & dosage ; Sitagliptin Phosphate/adverse effects ; Survival Analysis ; Tacrolimus/therapeutic use ; Transplantation, Homologous ; Young Adult
Czasopismo naukowe
Tytuł :
Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus.
Autorzy :
Orime K; Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama-City University , Yokohama, Japan.
Terauchi Y; Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama-City University , Yokohama, Japan.
Pokaż więcej
Źródło :
Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2020 Dec; Vol. 21 (17), pp. 2101-2114. Date of Electronic Publication: 2020 Sep 29.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Adamantane/*analogs & derivatives
Diabetes Mellitus, Type 2/*drug therapy
Dipeptides/*therapeutic use
Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
Hypoglycemic Agents/*therapeutic use
Adamantane/administration & dosage ; Adamantane/adverse effects ; Adamantane/therapeutic use ; Blood Glucose/analysis ; Diabetes Mellitus, Type 2/blood ; Dipeptides/administration & dosage ; Dipeptides/adverse effects ; Dipeptidyl-Peptidase IV Inhibitors/administration & dosage ; Dipeptidyl-Peptidase IV Inhibitors/adverse effects ; Heart Failure/chemically induced ; Humans ; Hypoglycemia/chemically induced ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/adverse effects ; Randomized Controlled Trials as Topic ; Sodium-Glucose Transporter 2 Inhibitors/administration & dosage ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł :
DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?
Autorzy :
Krejner-Bienias A; Department of Histology and Embryology, Medical University of Warsaw, Chalubinskiego 5, 02-004, Warsaw, Poland.
Grzela K; Department of Pediatric Pulmonology and Allergy, Medical University of Warsaw, Warsaw, Poland.
Grzela T; Department of Histology and Embryology, Medical University of Warsaw, Chalubinskiego 5, 02-004, Warsaw, Poland. .
Pokaż więcej
Źródło :
Archivum immunologiae et therapiae experimentalis [Arch Immunol Ther Exp (Warsz)] 2021 Feb 02; Vol. 69 (1), pp. 1. Date of Electronic Publication: 2021 Feb 02.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antiviral Agents/*therapeutic use
COVID-19/*drug therapy
Diabetes Mellitus, Type 2/*complications
Dipeptidyl Peptidase 4/*metabolism
Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
SARS-CoV-2/*drug effects
Antiviral Agents/pharmacology ; COVID-19/complications ; COVID-19/enzymology ; COVID-19/metabolism ; Dipeptidyl-Peptidase IV Inhibitors/pharmacology ; Humans
Czasopismo naukowe
Tytuł :
Cardiovascular and renal risk reduction in type 2 diabetes---which choice?
Autorzy :
Drueke TB; Centre de recherche en Epidémiologie et Santé des Populations (CESP), Institut National de la Santé et de la Recherche Médicale unité mixte de recherche (UMRS) 1018, Université Paris-Sud, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), and Université Paris-Saclay, Villejuif, France. Electronic address: .
Pokaż więcej
Źródło :
Kidney international [Kidney Int] 2021 Feb; Vol. 99 (2), pp. 322-323.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Diabetes Mellitus, Type 2*/epidemiology
Dipeptidyl-Peptidase IV Inhibitors*
Pharmaceutical Preparations*
Glucagon-Like Peptide-1 Receptor ; Humans ; Incretins ; Kidney ; Risk Reduction Behavior
Opinia redakcyjna
Tytuł :
Clinical Evidence of Evogliptin plus Metformin in Management of Type 2 Diabetes mellitus.
Autorzy :
Bajaj S; Director-Professor and Head of Medicine, MLN Medical College, Prayagraj.
Aiwale A; Senior Medical Advisor, Medical Department of Alkem Laboratory, Mumbai, Maharashtra.
Trailokya A; Deputy General Manager, Medical Department of Alkem Laboratory, Mumbai, Maharashtra.
Sharma A; President and CMO Medical Department of Alkem Laboratory, Mumbai, Maharashtra.
Pokaż więcej
Źródło :
The Journal of the Association of Physicians of India [J Assoc Physicians India] 2021 Feb; Vol. 69 (2), pp. 25-29.
Typ publikacji :
Journal Article
MeSH Terms :
Diabetes Mellitus, Type 2*/drug therapy
Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use
Metformin*/therapeutic use
Blood Glucose ; Drug Therapy, Combination ; Glycated Hemoglobin A ; Humans ; Hypoglycemic Agents/therapeutic use ; India ; Piperazines ; Russia
Czasopismo naukowe
Tytuł :
[Which place to be reserved to sulphonylureas and which precautions to be taken ?]
Autorzy :
Scheen AJ; Service de Diabétologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, CHU Liège, Belgique.
Pokaż więcej
Transliterated Title :
Comment je traite… Quelle place encore réserver aux sulfamides hypoglycémiants et avec quelles précautions ?
Źródło :
Revue medicale de Liege [Rev Med Liege] 2021 Jan; Vol. 76 (1), pp. 7-12.
Typ publikacji :
Practice Guideline
MeSH Terms :
Diabetes Mellitus, Type 2*/drug therapy
Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use
Sodium-Glucose Transporter 2 Inhibitors*
Aged ; Humans ; Hypoglycemic Agents/adverse effects ; Sulfonylurea Compounds
Tytuł :
In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors.
Autorzy :
Liakos A; Aristotle University Thessaloniki, Thessaloniki, Greece (A.L., A.T., E.B.).
Tsapas A; Aristotle University Thessaloniki, Thessaloniki, Greece (A.L., A.T., E.B.).
Bekiari E; Aristotle University Thessaloniki, Thessaloniki, Greece (A.L., A.T., E.B.).
Pokaż więcej
Źródło :
Annals of internal medicine [Ann Intern Med] 2020 Dec 15; Vol. 173 (12), pp. JC70.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Diabetes Mellitus, Type 2*/drug therapy
Diabetic Ketoacidosis*/chemically induced
Dipeptidyl-Peptidase IV Inhibitors*/adverse effects
Sodium-Glucose Transporter 2 Inhibitors*/adverse effects
Cohort Studies ; Glucose ; Humans ; Hypoglycemic Agents/adverse effects ; Sodium
Czasopismo naukowe
Tytuł :
Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease.
Autorzy :
Kornelius E; From (1)Chung Shan Medical University Hospital, Department of Internal Medicine, Division of Endocrinology and Metabolism,; School of Medicine of Chung Shan Medical University; Institute of Medicine of Chung Shan Medical University.
Huang CN; From (1)Chung Shan Medical University Hospital, Department of Internal Medicine, Division of Endocrinology and Metabolism,; School of Medicine of Chung Shan Medical University; Institute of Medicine of Chung Shan Medical University.
Lo SC; From (1)Chung Shan Medical University Hospital, Department of Internal Medicine, Division of Endocrinology and Metabolism,; Institute of Medicine of Chung Shan Medical University.
Wang YH; Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
Yang YS; From (1)Chung Shan Medical University Hospital, Department of Internal Medicine, Division of Endocrinology and Metabolism,; School of Medicine of Chung Shan Medical University; Institute of Medicine of Chung Shan Medical University. Electronic address: .
Pokaż więcej
Źródło :
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists [Endocr Pract] 2020 Dec; Vol. 26 (12), pp. 1486-1496.
Typ publikacji :
Journal Article
MeSH Terms :
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Diabetes Mellitus, Type 2*/epidemiology
Diabetic Nephropathies*/drug therapy
Diabetic Nephropathies*/epidemiology
Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use
Blood Glucose ; Glomerular Filtration Rate ; Humans ; Retrospective Studies ; Taiwan/epidemiology
Czasopismo naukowe
Tytuł :
Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy.
Autorzy :
Mirani M; Endocrinology and Diabetology Unit, Humanitas Clinical and Research Center, IRCCS, Milan, Italy .
Favacchio G; Endocrinology and Diabetology Unit, Humanitas Clinical and Research Center, IRCCS, Milan, Italy.
Carrone F; Endocrinology and Diabetology Unit, Humanitas Clinical and Research Center, IRCCS, Milan, Italy.
Betella N; Endocrinology and Diabetology Unit, Humanitas Clinical and Research Center, IRCCS, Milan, Italy.
Biamonte E; Endocrinology and Diabetology Unit, Humanitas Clinical and Research Center, IRCCS, Milan, Italy.
Morenghi E; Biostatistics Unit, Humanitas Clinical and Research Center, IRCCS, Milan, Italy.
Mazziotti G; Endocrinology and Diabetology Unit, Humanitas Clinical and Research Center, IRCCS, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Lania AG; Endocrinology and Diabetology Unit, Humanitas Clinical and Research Center, IRCCS, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Pokaż więcej
Źródło :
Diabetes care [Diabetes Care] 2020 Dec; Vol. 43 (12), pp. 3042-3049. Date of Electronic Publication: 2020 Oct 06.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Coronavirus*
Coronavirus Infections*
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Diabetes Mellitus, Type 2*/epidemiology
Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use
Pandemics*
Pneumonia, Viral*
Betacoronavirus ; Blood Glucose ; COVID-19 ; Humans ; Italy/epidemiology ; Risk Factors ; SARS-CoV-2 ; Sitagliptin Phosphate
Czasopismo naukowe
Tytuł :
Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38α, and NF-κB signaling.
Autorzy :
Khalil R; Department of Biochemistry, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt.
Shata A; Department of Clinical pharmacology, Faculty of Medicine, Mansoura University, Mansoura, Egypt; Department of Clinical Pharmacy, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt.
Abd El-Kader EM; Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt.
Sharaf H; Department of Clinical Pharmacy, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt.
Abdo WS; Department of Pathology, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt.
Amin NA; Department of Haematology, Theodor Bilharz Research Institute, Egypt.
Saber S; Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt. Electronic address: .
Pokaż więcej
Źródło :
Toxicology and applied pharmacology [Toxicol Appl Pharmacol] 2020 Nov 15; Vol. 407, pp. 115246. Date of Electronic Publication: 2020 Sep 19.
Typ publikacji :
Journal Article
MeSH Terms :
Carbon Tetrachloride Poisoning/*drug therapy
Dipeptidyl-Peptidase IV Inhibitors/*pharmacology
Liver Cirrhosis/*drug therapy
Signal Transduction/*drug effects
Vildagliptin/*pharmacology
Animals ; Carbon Tetrachloride Poisoning/pathology ; Cell Survival/drug effects ; Dipeptidyl-Peptidase IV Inhibitors/administration & dosage ; Dipeptidyl-Peptidase IV Inhibitors/therapeutic use ; Dose-Response Relationship, Drug ; Inflammation Mediators/metabolism ; Liver Cirrhosis/chemically induced ; Liver Cirrhosis/pathology ; Liver Function Tests ; MAP Kinase Signaling System/drug effects ; Male ; Mice ; NF-kappa B/drug effects ; Phosphorylation ; Primary Cell Culture ; Rats ; Survival ; Vildagliptin/administration & dosage ; Vildagliptin/therapeutic use ; p38 Mitogen-Activated Protein Kinases/drug effects
Czasopismo naukowe
Tytuł :
In vitro modulation of glucagon-like peptide release by DPP-IV inhibitory polyphenol-polysaccharide conjugates of sprouted quinoa yoghurt.
Autorzy :
Obaroakpo JU; Institute of Food Science and Technology, Chinese Academy of Agricultural Science, Beijing 100193, China; Department of Food Science and Technology, Auchi Polytechnic, Auchi, Edo State, Nigeria.
Liu L; Beijing Nutrition Resources Institute, Beijing 100069, China.
Zhang S; Institute of Food Science and Technology, Chinese Academy of Agricultural Science, Beijing 100193, China.
Lu J; Institute of Food Science and Technology, Chinese Academy of Agricultural Science, Beijing 100193, China.
Liu L; Institute of Food Science and Technology, Chinese Academy of Agricultural Science, Beijing 100193, China.
Pang X; Institute of Food Science and Technology, Chinese Academy of Agricultural Science, Beijing 100193, China; Beijing Advanced Innovation Center for Food Nutrition and Human Health, Beijing Technology & Business University (BTBU), Beijing 100048, China. Electronic address: .
Lv J; Institute of Food Science and Technology, Chinese Academy of Agricultural Science, Beijing 100193, China. Electronic address: .
Pokaż więcej
Źródło :
Food chemistry [Food Chem] 2020 Sep 15; Vol. 324, pp. 126857. Date of Electronic Publication: 2020 Apr 18.
Typ publikacji :
Journal Article
MeSH Terms :
Chenopodium quinoa/*chemistry
Dipeptidyl-Peptidase IV Inhibitors/*chemistry
Glucagon-Like Peptide 1/*metabolism
Polyphenols/*chemistry
Polysaccharides/*chemistry
Yogurt/*analysis
Calcium/metabolism ; Cell Line ; Cell Survival/drug effects ; Chenopodium quinoa/growth & development ; Chenopodium quinoa/metabolism ; Chromatography, High Pressure Liquid ; Dipeptidyl-Peptidase IV Inhibitors/metabolism ; Dipeptidyl-Peptidase IV Inhibitors/pharmacology ; Germination ; Humans ; Polyphenols/analysis ; Polyphenols/isolation & purification ; Polysaccharides/analysis ; Polysaccharides/isolation & purification ; Proglucagon/antagonists & inhibitors ; Proglucagon/genetics ; Proglucagon/metabolism ; Proprotein Convertase 1/antagonists & inhibitors ; Proprotein Convertase 1/genetics ; Proprotein Convertase 1/metabolism
Czasopismo naukowe
Tytuł :
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.
Autorzy :
Deacon CF; Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. .
Pokaż więcej
Źródło :
Nature reviews. Endocrinology [Nat Rev Endocrinol] 2020 Nov; Vol. 16 (11), pp. 642-653. Date of Electronic Publication: 2020 Sep 14.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Diabetes Mellitus, Type 2/*drug therapy
Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
Hypoglycemic Agents/*therapeutic use
Dipeptidyl-Peptidase IV Inhibitors/adverse effects ; Humans ; Hypoglycemic Agents/adverse effects
Czasopismo naukowe
Tytuł :
Cardiovascular safety of Glimepiride: An indirect comparison from CAROLINA and CARMELINA.
Autorzy :
Ghosh S; Department of Endocrinology, Institute of Post Graduate Medical Education & Research, Kolkata, India.
Mukhopadhyay P; Department of Endocrinology, Institute of Post Graduate Medical Education & Research, Kolkata, India.
Pandey P; Department of Pharmacy, RV Northland Institute, Greater Noida, UP, India.
Chatterjee P; Department of Endocrinology, Apollo Gleaneagles Hospital, Kolkata, West Bengal, India.
Pandit K; Department of Endocrinology, Institute of Post Graduate Medical Education & Research, Kolkata, India.
Pokaż więcej
Źródło :
Diabetes & vascular disease research [Diab Vasc Dis Res] 2020 Nov-Dec; Vol. 17 (6), pp. 1479164120973653.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Cardiovascular Diseases/*prevention & control
Diabetes Mellitus, Type 2/*drug therapy
Diabetes Mellitus, Type 2/*mortality
Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
Hypoglycemic Agents/*therapeutic use
Linagliptin/*therapeutic use
Sulfonylurea Compounds/*therapeutic use
Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/mortality ; Clinical Trials as Topic ; Diabetes Mellitus, Type 2/diagnosis ; Dipeptidyl-Peptidase IV Inhibitors/adverse effects ; Evidence-Based Medicine ; Heart Disease Risk Factors ; Humans ; Hypoglycemic Agents/adverse effects ; Linagliptin/adverse effects ; Risk Assessment ; Sulfonylurea Compounds/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights.
Autorzy :
Stoian AP; Diabetes, Nutrition and Metabolic Diseases Department, 87267'Carol Davila' University of Medicine, Bucharest, Romania.
Papanas N; Diabetes Center, Second Department of Internal Medicine, 387479Democritus University of Thrace, University Hospital of Alexandroupolis, Greece.
Prazny M; Third Department of Internal Medicine, First Faculty of Medicine, 37740Charles University, Prague, Czech Republic.
Rizvi AA; Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, 1371Emory University, Atlanta, GA, USA.; Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of South Carolina, Columbia, SC, USA.
Rizzo M; Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of South Carolina, Columbia, SC, USA.; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), 18998University of Palermo, Italy.
Pokaż więcej
Źródło :
Journal of cardiovascular pharmacology and therapeutics [J Cardiovasc Pharmacol Ther] 2020 Nov; Vol. 25 (6), pp. 494-496. Date of Electronic Publication: 2020 Jul 03.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Coronavirus Infections/*drug therapy
Coronavirus Infections/*epidemiology
Diabetes Mellitus, Type 2/*drug therapy
Diabetes Mellitus, Type 2/*epidemiology
Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
Incretins/*therapeutic use
Pneumonia, Viral/*drug therapy
Pneumonia, Viral/*epidemiology
Betacoronavirus ; COVID-19 ; Dipeptidyl-Peptidase IV Inhibitors/pharmacology ; Glucagon-Like Peptide-1 Receptor/metabolism ; Humans ; Hypoglycemic Agents ; Incretins/pharmacology ; Inflammation Mediators/metabolism ; Pandemics ; SARS-CoV-2 ; Severity of Illness Index
Czasopismo naukowe
Tytuł :
Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes.
Autorzy :
Jung S; Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander-University, Ulmenweg 18, 91054 Erlangen-Nuremberg, Germany.; Department of Cardiology and Angiology, University Hospital Erlangen, Friedrich-Alexander-University, Ulmenweg 18, 91054 Erlangen, Germany.
Bosch A; Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander-University, Ulmenweg 18, 91054 Erlangen-Nuremberg, Germany.
Kannenkeril D; Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander-University, Ulmenweg 18, 91054 Erlangen-Nuremberg, Germany.
Karg MV; Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander-University, Ulmenweg 18, 91054 Erlangen-Nuremberg, Germany.
Striepe K; Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander-University, Ulmenweg 18, 91054 Erlangen-Nuremberg, Germany.
Bramlage P; Institute for Pharmacology and Preventive Medicine, Bahnhofstraße 20, 49661 Cloppenburg, Germany.
Ott C; Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander-University, Ulmenweg 18, 91054 Erlangen-Nuremberg, Germany.; Department of Nephrology and Hypertension, Paracelsus Medical School, Bresauler Straße 201, 90471 Nuremberg, Germany.
Schmieder RE; Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander-University, Ulmenweg 18, 91054 Erlangen-Nuremberg, Germany.
Pokaż więcej
Źródło :
European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2020 Nov 01; Vol. 6 (6), pp. 364-371.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Arterial Pressure/*drug effects
Benzhydryl Compounds/*therapeutic use
Blood Glucose/*drug effects
Diabetes Mellitus, Type 2/*drug therapy
Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
Glucosides/*therapeutic use
Linagliptin/*therapeutic use
Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
Vascular Stiffness/*drug effects
Aged ; Benzhydryl Compounds/adverse effects ; Biomarkers/blood ; Blood Glucose/metabolism ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/physiopathology ; Dipeptidyl-Peptidase IV Inhibitors/adverse effects ; Drug Therapy, Combination ; Female ; Germany ; Glucosides/adverse effects ; Humans ; Insulin Glargine/therapeutic use ; Linagliptin/adverse effects ; Male ; Metformin/therapeutic use ; Middle Aged ; Prospective Studies ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Lowering the risk of Parkinson's disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes.
Autorzy :
Bayram E; Parkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego, La Jolla, CA, USA.
Litvan I; Parkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego, La Jolla, CA, USA.
Pokaż więcej
Źródło :
Brain : a journal of neurology [Brain] 2020 Oct 01; Vol. 143 (10), pp. 2868-2871.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Comment
MeSH Terms :
Diabetes Mellitus, Type 2*/drug therapy
Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use
Parkinson Disease*/drug therapy
Cohort Studies ; Dipeptidyl Peptidase 4 ; Glucagon-Like Peptide 1 ; Humans ; Hypoglycemic Agents/therapeutic use
Czasopismo naukowe
Tytuł :
Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study.
Autorzy :
Chen YC; Department of Family Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Chen TH; Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan.; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Sun CC; Department of Ophthalmology, Chang Gung Memorial Hospital, Keelung, Taiwan.; Department of Chinese Medicine, Chang Gung University, Taoyuan, Taiwan.
Chen JY; Department of Family Medicine, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Chang SS; Department of Family Medicine, Taipei Medical University Hospital, Taipei City, Taiwan.; Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Yeung L; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Department of Ophthalmology, Chang Gung Memorial Hospital, Keelung, Taiwan.
Tsai YW; College of Medicine, Chang Gung University, Taoyuan, Taiwan. .; Department of Family Medicine, Chang Gung Memorial Hospital, Keelung Branch, No. 222, Maijin Road, Keelung, Taiwan. .; Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan. .
Pokaż więcej
Źródło :
Acta diabetologica [Acta Diabetol] 2020 Oct; Vol. 57 (10), pp. 1181-1192. Date of Electronic Publication: 2020 Apr 21.
Typ publikacji :
Journal Article
MeSH Terms :
Autoimmune Diseases/*epidemiology
Diabetes Mellitus, Type 2/*drug therapy
Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Autoimmune Diseases/chemically induced ; Cohort Studies ; Databases, Factual ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/epidemiology ; Dipeptidyl-Peptidase IV Inhibitors/adverse effects ; Female ; Humans ; Hypoglycemic Agents/adverse effects ; Incidence ; Male ; Middle Aged ; Retrospective Studies ; Risk Factors ; Taiwan/epidemiology ; Young Adult
Czasopismo naukowe
Tytuł :
The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.
Autorzy :
Jin Y; Department of Internal Medicine, Hebei Medical University, Shijiazhuang, 050017, Hebei, People's Republic of China.; Endocrinology Department, Hebei General Hospital, Shijiazhuang, 050051, Hebei, People's Republic of China.
Zhao H; Endocrinology Department, Hebei General Hospital, Shijiazhuang, 050051, Hebei, People's Republic of China.
Hou Y; Department of Internal Medicine, Hebei Medical University, Shijiazhuang, 050017, Hebei, People's Republic of China.; Endocrinology Department, Hebei General Hospital, Shijiazhuang, 050051, Hebei, People's Republic of China.
Song G; Department of Internal Medicine, Hebei Medical University, Shijiazhuang, 050017, Hebei, People's Republic of China. .; Endocrinology Department, Hebei General Hospital, Shijiazhuang, 050051, Hebei, People's Republic of China. .
Pokaż więcej
Źródło :
Acta diabetologica [Acta Diabetol] 2020 Oct; Vol. 57 (10), pp. 1129-1144. Date of Electronic Publication: 2020 Apr 16.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Cognition/*drug effects
Diabetes Mellitus, Type 2/*drug therapy
Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
Glucagon-Like Peptide-1 Receptor/*agonists
Hypoglycemic Agents/*therapeutic use
Adult ; Cognition/physiology ; Diabetes Mellitus, Type 2/psychology ; Dipeptidyl-Peptidase IV Inhibitors/pharmacology ; Glucagon-Like Peptide 1/analogs & derivatives ; Glucagon-Like Peptide 1/therapeutic use ; Humans ; Hypoglycemic Agents/pharmacology ; Incretins/therapeutic use
Czasopismo naukowe
Tytuł :
Inhibitory effect of chestnut (Castanea mollissima Blume) inner skin extract on the activity of α-amylase, α-glucosidase, dipeptidyl peptidase IV and in vitro digestibility of starches.
Autorzy :
Zhang Y; Department of Food Science and Engineering, College of Biological Sciences and Technology, Beijing Key Laboratory of Forest Food Process and Safety, Beijing Forestry University, Beijing 100083, China.
Yang Z; Department of Food Science and Engineering, College of Biological Sciences and Technology, Beijing Key Laboratory of Forest Food Process and Safety, Beijing Forestry University, Beijing 100083, China.
Liu G; Department of Food Science and Engineering, College of Biological Sciences and Technology, Beijing Key Laboratory of Forest Food Process and Safety, Beijing Forestry University, Beijing 100083, China.
Wu Y; Beijing Center for Physical and Chemical Analysis, Beijing Food Safety Analysis and Testing Engineering Research Center, Beijing Academy of Science and Technology, Beijing 100089, China.
Ouyang J; Department of Food Science and Engineering, College of Biological Sciences and Technology, Beijing Key Laboratory of Forest Food Process and Safety, Beijing Forestry University, Beijing 100083, China. Electronic address: .
Pokaż więcej
Źródło :
Food chemistry [Food Chem] 2020 Sep 15; Vol. 324, pp. 126847. Date of Electronic Publication: 2020 Apr 18.
Typ publikacji :
Journal Article
MeSH Terms :
Dipeptidyl-Peptidase IV Inhibitors/*pharmacology
Fagaceae/*chemistry
Glycoside Hydrolase Inhibitors/*pharmacology
Plant Extracts/*pharmacology
Biological Availability ; Catechin/analogs & derivatives ; Catechin/pharmacology ; Dipeptidyl Peptidase 4/chemistry ; Dipeptidyl Peptidase 4/metabolism ; Dipeptidyl-Peptidase IV Inhibitors/chemistry ; Flavonoids/analysis ; Glycoside Hydrolase Inhibitors/chemistry ; Nuts/chemistry ; Plant Extracts/chemistry ; Starch/pharmacokinetics ; alpha-Amylases/antagonists & inhibitors ; alpha-Amylases/chemistry ; alpha-Glucosidases/chemistry
Czasopismo naukowe
Tytuł :
Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.
Autorzy :
Zhang C; Haisco Pharmaceutical Group Company Ltd., 136 Baili Road, Wenjiang district, Chengdu 611130, China.
Ye F; Haisco Pharmaceutical Group Company Ltd., 136 Baili Road, Wenjiang district, Chengdu 611130, China.
Wang J; Haisco Pharmaceutical Group Company Ltd., 136 Baili Road, Wenjiang district, Chengdu 611130, China.
He P; Haisco Pharmaceutical Group Company Ltd., 136 Baili Road, Wenjiang district, Chengdu 611130, China.
Lei M; Haisco Pharmaceutical Group Company Ltd., 136 Baili Road, Wenjiang district, Chengdu 611130, China.
Huang L; Haisco Pharmaceutical Group Company Ltd., 136 Baili Road, Wenjiang district, Chengdu 611130, China.
Huang A; Haisco Pharmaceutical Group Company Ltd., 136 Baili Road, Wenjiang district, Chengdu 611130, China.
Tang P; Haisco Pharmaceutical Group Company Ltd., 136 Baili Road, Wenjiang district, Chengdu 611130, China.
Lin H; Haisco Pharmaceutical Group Company Ltd., 136 Baili Road, Wenjiang district, Chengdu 611130, China.
Liao Y; Haisco Pharmaceutical Group Company Ltd., 136 Baili Road, Wenjiang district, Chengdu 611130, China.
Liang Y; Haisco Pharmaceutical Group Company Ltd., 136 Baili Road, Wenjiang district, Chengdu 611130, China.
Ni J; Haisco Pharmaceutical Group Company Ltd., 136 Baili Road, Wenjiang district, Chengdu 611130, China.
Yan P; Haisco Pharmaceutical Group Company Ltd., 136 Baili Road, Wenjiang district, Chengdu 611130, China.
Pokaż więcej
Źródło :
Journal of medicinal chemistry [J Med Chem] 2020 Jul 09; Vol. 63 (13), pp. 7108-7126. Date of Electronic Publication: 2020 Jun 12.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Design*
Diabetes Mellitus, Type 2/*drug therapy
Dipeptidyl Peptidase 4/*metabolism
Dipeptidyl-Peptidase IV Inhibitors/*chemical synthesis
Dipeptidyl-Peptidase IV Inhibitors/*pharmacology
Heterocyclic Compounds, 2-Ring/*chemical synthesis
Heterocyclic Compounds, 2-Ring/*pharmacology
Pyrans/*chemical synthesis
Pyrans/*pharmacology
Animals ; Chemistry Techniques, Synthetic ; Dipeptidyl-Peptidase IV Inhibitors/chemistry ; Dipeptidyl-Peptidase IV Inhibitors/pharmacokinetics ; Heterocyclic Compounds, 2-Ring/chemistry ; Heterocyclic Compounds, 2-Ring/pharmacokinetics ; Macaca mulatta ; Male ; Mice ; Pyrans/chemistry ; Pyrans/pharmacokinetics ; Tissue Distribution
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies